Manufacturing process with Chemical Reactions and mass Balance for 6 Pharmaceutical Drugs

Ashok K Rathoure, Savita Goyal Aggarwal

Abstract


Diclofenac is a non-steroidal anti-inflammatory drug. Bifonazole is a substituted imidazole antifungal agent structurally related to other drugs in this group. It possesses a broad spectrum of activity in vitro against dermatophytes, moulds, yeasts, dimorphic fungi and some Gram-positive bacteria. Aceclofenac is used to relieve pain in the conditions like osteoarthritis, rheumatoid Arthritis and ankylosing spondylitis. Clotrimazole is used to treat yeast infections of the vagina, mouth and skin such as athlete’s foot, jock itch and body ringworm. It can also be used to prevent oral thrush in certain patients. Dihydralazine sulfate is a vasodilator and an antihypertensive agent. It relaxes arterial smooth muscle by inhibiting the accumulation of intracellular free calcium. By relaxing vascular smooth muscle, vasodilators act to decrease peripheral resistance. Pyridoxine hydrochloride is the 4-methanol form of Vitamin B6 which is converted
to Pyridoxal phosphate which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Here, we have presented the manufacturing process along with mass balance for 6 pharmaceutical drugs.


Keywords


Aceclofenac, Bifonazole, Clotrimazole, Drugs, Diclofenac Sodium, Pyridoxine Acetonide Hydrochloride

Full Text:

PDF

References


Agius, R. (1989). Occupational exposure limits for

therapeutic substances. Ann. Occ. Hyg. 33: 555-562.

Barry, S Strandgaard, D I Graham, U G Svendsen, O

Braendstrup, O B Paulson (1984). Cerebral blood

flow during dihydralazine-induced hypotension in

hypertensive rats. Stroke, 15(15).

Crowley Peter D and Gallagher Helen C (2014).

Clotrimazole as a pharmaceutical: Past, present and

future. Journal of Applied Microbiology 117(3) DOI

1111/jam.12554.

Garg G., Swarnlata Saraf and S. Saraf (2007).

Simultaneous estimation of aceclofenac, paracetamol

and chlorzoxazone in tablets. Indian J Pharm Sci 2007,

(5): 692-694.

Gennaro, A. (1990). Remington’s Pharmaceutical

Sciences, 18th edition. Easton, PA: Mack Publishing

Company.

Goa, K.L. and Chrisp, P. (1992). Ocular diclofenac. A

review of its pharmacology and clinical use in cataract

surgery, and potential in other inflammatory ocular

conditions. Drugs Aging 2:473-486.

Hanneke Garbis, Margreet Rost van Tonningen, Minke

Reuvers (2007).Anti-infective agents Hardman, JA

Gilman and L Limbird (1996). Goodman and Gilman’s

The Pharmacologic Basis of Therapeutics. New York:

McGraw Hill Co. In: Drugs During Pregnancy and

Lactation (2nd Edi). Ed Christof Schaefer, Paul Peters

and Richard K. Miller, pp 123-177.

Kato, M., Nishida S, Kitasato H, Sakata N, Kawai S.

(2001). Cyclooxygenase-1 and cyclooxygenase-2

selectivity of non-steroidal anti-inflammatory drugs:

investigation using human peripheral monocytes. J.

Pharm. Pharmacol. 53:1679-1685.

Klabunde, T., Petrassi HM, Oza VB, Raman P, Kelly

JW, Sacchettini JC. (2000). Rational design of potent

human transthyretin amyloid disease inhibitors. Nat.

Struct. Biol. 7:312-321.

Knowles Helen J, Ya-Min Tian, David R Mole, Adrian

L Harris (2004). Novel mechanism of action for

hydralazine: Induction of hypoxia-inducible factor-1

alpha, vascular endothelial growth factor, and

angiogenesis by inhibition of prolyl hydroxylases.

Circulation Research, 95(2004) DOI 10.1161/01.

RES.0000134924.89412.70.

Kurowski, M., and Dunky, A. (1992). Pharmacokinetics

and metabolism of oral diosmin in healthy volunteers.

Int. J. Clin. Pharmacol. Ther. Toxicol. 30(1):29-33.

Lackner TE and Clissold SP. (1989). Bifonazole. A review

of its antimicrobial activity and therapeutic use in

superficial mycoses. Drugs. 38(2):204-25.

Manuchair Ebadi (2007). Desk Reference of Clinical

Pharmacology, Second Edition CRC Press New York

Merlos, M., M. L. Vericat, J. García-Rafanell, J. Forn

(1996). Topical anti-inflammatory properties of

flutrimazole, a new imidazole antifungal agent.

Inflamm. Res. 45, 20-25.

Naumann, B, EV Sargent, BS Starkman, WJ Fraser,

GT Becker and GD Kirk (1996). Performance-based

exposure control limits for pharmaceutical active

ingredients Am Ind Hyg Assoc J 57: 33-42.

Sarfaraz K. Niazi (2009). Handbook of Pharmaceutical

Manufacturing Formulations: Over-the-Counter

Products. Informa Healthcare USA.

Sargent, E. and G Kirk (1988). Establishing airborne

exposure control limits in the pharmaceutical industry.

Am Ind Hyg Assoc J 49:309-313.

Semalty A., Mona Semalty, B.S. Rawat, D.Singh, and

M. S. M. Rawat (2010). Development and evaluation

of pharmacosomes of aceclofenac. Indian J Pharm Sci,

, 72 (5): 576-581.

Teichman, R, F Fallon and P Brandt-Rauf (1988). Health

effects on workers in the pharmaceutical industry: A

review. J Soc Occ Med 38: 55-57.

Vietri, M., C. De Santi, A. Pietrabissa, F. Mosca, G.

M. Pacifici (2000). Inhibition of human liver phenol

sulfotransferase by nonsteroidal anti-inflammatory

drugs. Eur J. Clin. Pharmacol. 56:81-87.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Journal of Drug Discovery and Development

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.